

# Robert L Atmar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2389461/publications.pdf>

Version: 2024-02-01

242  
papers

25,891  
citations

9234

74  
h-index

7136

153  
g-index

249  
all docs

249  
docs citations

249  
times ranked

28760  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort”™. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e239-e239.	0.5	8
2	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
3	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	13.9	338
4	Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations “ United States, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 290-292.	9.0	8
5	Association of secretor status and recent norovirus infection with gut microbiome diversity metrics in a Veterans Affairs population. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac125.	0.4	0
6	Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity. <i>Nature Communications</i> , 2022, 13, 1241.	5.8	19
7	Antiviral Activity of Olanexidine-Containing Hand Rub against Human Noroviruses. <i>MBio</i> , 2022, 13, e0284821.	1.8	9
8	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 888-899.	5.2	62
9	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100679.	3.3	100
10	Use of Human Intestinal Enteroids to Evaluate Persistence of Infectious Human Norovirus in Seawater. <i>Emerging Infectious Diseases</i> , 2022, 28, 1475-1479.	2.0	18
11	New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	20
12	Birth Cohort Studies: Toward Understanding Protective Immunity to Human Noroviruses. <i>Clinical Infectious Diseases</i> , 2021, 72, 230-232.	2.9	2
13	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-12.	26.7	37
14	New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids. <i>MSphere</i> , 2021, 6, .	1.3	78
15	Norovirus in Cancer Patients: A Review. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab126.	0.4	6
16	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Infectious Diseases</i> , 2021, 224, 1372-1382.	1.9	10
17	SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab180.	0.4	16
18	Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. <i>Journal of Infectious Diseases</i> , 2021, 224, 1712-1719.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Bile Goes Viral. <i>Viruses</i> , 2021, 13, 998.	1.5	7
20	Case-based audit and feedback around a decision aid improved antibiotic choice and duration for uncomplicated cystitis in primary care clinics. <i>Family Medicine and Community Health</i> , 2021, 9, e000834.	0.6	4
21	â€˜String Testâ€™™ for Hypermucoviscous <i>Klebsiella pneumoniae</i> . <i>American Journal of Medicine</i> , 2021, 134, e520-e521.	0.6	9
22	Glycan Recognition in Human Norovirus Infections. <i>Viruses</i> , 2021, 13, 2066.	1.5	15
23	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	5.2	119
24	Norovirus Protease Structure and Antivirals Development. <i>Viruses</i> , 2021, 13, 2069.	1.5	3
25	Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-16.	26.7	92
26	700. Risk Factors and Molecular Epidemiology of Acute and Chronic Norovirus Infection at a Large Tertiary Care Cancer Center. <i>Open Forum Infectious Diseases</i> , 2021, 8, S450-S451.	0.4	0
27	Improving Influenza Prevention: Modest Changes With Large Effects. <i>Clinical Infectious Diseases</i> , 2020, 70, 2503-2504.	2.9	0
28	Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1700-1710.	3.3	75
29	High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing. <i>Journal of Virology</i> , 2020, 95, .	1.5	10
30	Histo-blood group antigens of glycosphingolipids predict susceptibility of human intestinal enteroids to norovirus infection. <i>Journal of Biological Chemistry</i> , 2020, 295, 15974-15987.	1.6	10
31	Human norovirus exhibits strain-specific sensitivity to host interferon pathways in human intestinal enteroids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23782-23793.	3.3	63
32	Postacute COVID-19: An Overview and Approach to Classification. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa509.	0.4	128
33	An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3138-3145.	1.4	4
34	Influenza Challenge Models: Ready for Prime Time?. <i>Clinical Infectious Diseases</i> , 2020, 71, 3012-3013.	2.9	0
35	Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection. <i>MBio</i> , 2020, 11, .	1.8	65
36	Creating an Outpatient-Specific Antibigram to Guide Treatment for Urinary Tract Infections. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s182-s183.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	13.9	5,834
38	1098. Norovirus Infection in Cancer Patients Undergoing Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T). <i>Open Forum Infectious Diseases</i> , 2020, 7, S578-S579.	0.4	1
39	Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. <i>Journal of Clinical Investigation</i> , 2020, 130, 6194-6197.	3.9	71
40	Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2020–21 Influenza Season. <i>MMWR Recommendations and Reports</i> , 2020, 69, 1-24.	26.7	258
41	1122. Improving Knowledge of Infectious Disease Fellows Regarding Infection Prevention & Antibiotic Stewardship Using a Multi-Faceted Approach. <i>Open Forum Infectious Diseases</i> , 2020, 7, S591-S591.	0.4	0
42	Dialysis Catheter–related Bloodstream Infections in Patients Receiving Hemodialysis on an Emergency-only Basis: A Retrospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2019, 68, 1011-1016.	2.9	21
43	Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. <i>Vaccine</i> , 2019, 37, 5161-5170.	1.7	4
44	Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges. <i>Viruses</i> , 2019, 11, 638.	1.5	84
45	Searching for Improved Flu Vaccines – The Time Is Now. <i>Journal of Infectious Diseases</i> , 2019, 221, 1-4.	1.9	4
46	Comparison of Microneutralization and Histo-Blood Group Antigen – Blocking Assays for Functional Norovirus Antibody Detection. <i>Journal of Infectious Diseases</i> , 2019, 221, 739-743.	1.9	34
47	Human Norovirus Histo-Blood Group Antigen (HBGA) Binding Sites Mediate the Virus Specific Interactions with Lettuce Carbohydrates. <i>Viruses</i> , 2019, 11, 833.	1.5	12
48	Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz352.	0.4	26
49	Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. <i>Journal of Infectious Diseases</i> , 2019, 220, 603-614.	1.9	22
50	Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. <i>Vaccine</i> , 2019, 37, 2561-2568.	1.7	6
51	Active Surveillance for Norovirus in a US Veterans Affairs Patient Population, Houston, Texas, 2015–2016. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz115.	0.4	6
52	Effects of Child and Maternal Histo-Blood Group Antigen Status on Symptomatic and Asymptomatic Enteric Infections in Early Childhood. <i>Journal of Infectious Diseases</i> , 2019, 220, 151-162.	1.9	47
53	2650. Evaluating Antiviral Agents for Human Noroviruses Using a Human Intestinal Enteroid Model. <i>Open Forum Infectious Diseases</i> , 2019, 6, S927-S928.	0.4	0
54	Norovirus in health care and implications for the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 348-355.	1.3	18

#	ARTICLE	IF	CITATIONS
55	An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2019, 219, 410-414.	1.9	13
56	Influenza Vaccines After 7 Decades: Still on the Learning Curve. <i>Journal of Infectious Diseases</i> , 2019, 220, 1240-1242.	1.9	0
57	Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey – Houston, Texas, 2017. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 469-473.	9.0	24
58	Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recommendations and Reports</i> , 2019, 68, 1-14.	26.7	87
59	2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S748-S748.	0.4	0
60	652. What Is Blood Got to Do with It? Genetic Susceptibility to Norovirus and Rotavirus Infection: Results From the SUPERNOVA Network. <i>Open Forum Infectious Diseases</i> , 2018, 5, S236-S237.	0.4	0
61	Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. <i>Gastroenterology</i> , 2018, 155, 1898-1907.	0.6	59
62	Human noroviruses: recent advances in a 50-year history. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 422-432.	1.3	103
63	Glycan recognition in globally dominant human rotaviruses. <i>Nature Communications</i> , 2018, 9, 2631.	5.8	63
64	Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation. <i>Emerging Infectious Diseases</i> , 2018, 24, 1453-1464.	2.0	179
65	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. <i>Vaccine</i> , 2017, 35, 1675-1682.	1.7	17
66	B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. <i>Vaccine Journal</i> , 2017, 24, .	3.2	17
67	Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
68	Structural features of glycan recognition among viral pathogens. <i>Current Opinion in Structural Biology</i> , 2017, 44, 211-218.	2.6	25
69	Deep sequencing of phage-displayed peptide libraries reveals sequence motif that detects norovirus. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 129-139.	1.0	9
70	Prospects and Challenges in the Development of a Norovirus Vaccine. <i>Clinical Therapeutics</i> , 2017, 39, 1537-1549.	1.1	95
71	Tularemia vaccine: Safety, reactogenicity, –Take–skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain – A phase 2 randomized clinical Trial. <i>Vaccine</i> , 2017, 35, 4730-4737.	1.7	30
72	Community Environmental Contamination of Toxigenic Clostridium difficile. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx018.	0.4	44

#	ARTICLE	IF	CITATIONS
73	Active Surveillance to Quantify the Burden of Norovirus in a U.S. Veterans Affairs (VA) Patient Population, Houston, 2015–2016. <i>Open Forum Infectious Diseases</i> , 2017, 4, S317-S317.	0.4	0
74	Immune Response. , 2017, , 89-106.		0
75	Identification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses. <i>PLoS ONE</i> , 2017, 12, e0170162.	1.1	6
76	Human Caliciviruses. , 2016, , 1189-1208.		0
77	Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. <i>Journal of General Virology</i> , 2016, 97, 2291-2300.	1.3	85
78	Prevalence of hypervirulent <i>Klebsiella pneumoniae</i> -associated genes <i>rmpA</i> and <i>magA</i> in two tertiary hospitals in Houston, TX, USA. <i>Journal of Medical Microbiology</i> , 2016, 65, 1047-1048.	0.7	21
79	Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2016, 214, 845-853.	1.9	49
80	Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays. <i>Scientific Reports</i> , 2016, 6, 24297.	1.6	11
81	Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. <i>Journal of Virology</i> , 2016, 90, 8906-8923.	1.5	34
82	Replication of human noroviruses in stem cell–derived human enteroids. <i>Science</i> , 2016, 353, 1387-1393.	6.0	1,056
83	Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5830-E5837.	3.3	41
84	Engineering Specificity from Broad to Narrow: Design of a $\beta$ -Lactamase Inhibitory Protein (BLIP) Variant That Exclusively Binds and Detects KPC $\beta$ -Lactamase. <i>ACS Infectious Diseases</i> , 2016, 2, 969-979.	1.8	10
85	Antiviral targets of human noroviruses. <i>Current Opinion in Virology</i> , 2016, 18, 117-125.	2.6	35
86	Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. <i>Vaccine</i> , 2016, 34, 547-554.	1.7	4
87	Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. <i>Vaccine Journal</i> , 2016, 23, 181-183.	3.2	9
88	Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1211-1213.	1.9	5
89	Shunting in cryptococcal meningitis. <i>Journal of Neurosurgery</i> , 2016, 125, 177-186.	0.9	44
90	Correlates of Protection against Norovirus Infection and Disease—Where Are We Now, Where Do We Go?. <i>PLoS Pathogens</i> , 2016, 12, e1005334.	2.1	44

#	ARTICLE	IF	CITATIONS
91	Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding. <i>PLoS Pathogens</i> , 2016, 12, e1005719.	2.1	27
92	In the Endemic Setting, <i>Clostridium difficile</i> Ribotype O27 Is Virulent But Not Hypervirulent. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1318-1323.	1.0	38
93	Reply to Kirby et al. <i>Journal of Infectious Diseases</i> , 2015, 211, 167-167.	1.9	2
94	Acute Gastroenteritis Viruses. , 2015, , 1083-1103.		0
95	Mucosal and Cellular Immune Responses to Norwalk Virus. <i>Journal of Infectious Diseases</i> , 2015, 212, 397-405.	1.9	81
96	Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. <i>Vaccine</i> , 2015, 33, 568-576.	1.7	41
97	Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2015, 211, 870-878.	1.9	223
98	Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 237.	3.8	124
99	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.	1.7	92
100	Serological Correlates of Protection against a GII.4 Norovirus. <i>Vaccine Journal</i> , 2015, 22, 923-929.	3.2	109
101	Experimental Human Infection with Norwalk Virus Elicits a Surrogate Neutralizing Antibody Response with Cross-Genogroup Activity. <i>Vaccine Journal</i> , 2015, 22, 221-228.	3.2	32
102	Norovirus Antigen Detection with a Combination of Monoclonal and Single-Chain Antibodies. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3916-3918.	1.8	11
103	Mapping Broadly Reactive Norovirus Genogroup I and II Monoclonal Antibodies. <i>Vaccine Journal</i> , 2015, 22, 168-177.	3.2	15
104	Characterization of Cross-Reactive Norovirus-Specific Monoclonal Antibodies. <i>Vaccine Journal</i> , 2015, 22, 160-167.	3.2	27
105	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. <i>Vaccine</i> , 2015, 33, 163-173.	1.7	3
106	Sensitive Detection of Norovirus Using Phage Nanoparticle Reporters in Lateral-Flow Assay. <i>PLoS ONE</i> , 2015, 10, e0126571.	1.1	37
107	Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections – A Prospective Cohort Study. <i>PLoS Pathogens</i> , 2015, 11, e1004869.	2.1	147
108	606Noroviruses (NoVs) as a Cause of Diarrhea in Immunocompromised Pediatric Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S27-S28.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Seroepidemiology of Norovirus-Associated Travelers' Diarrhea. <i>Journal of Travel Medicine</i> , 2014, 21, 6-11.	1.4	28
110	Epidemiology of human noroviruses and updates on vaccine development. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 25-33.	1.0	156
111	Determination of the 50% Human Infectious Dose for Norwalk Virus. <i>Journal of Infectious Diseases</i> , 2014, 209, 1016-1022.	1.9	261
112	Development of a Gaussia Luciferase-Based Human Norovirus Protease Reporter System: Cell Type-Specific Profile of Norwalk Virus Protease Precursors and Evaluation of Inhibitors. <i>Journal of Virology</i> , 2014, 88, 10312-10326.	1.5	8
113	Structural basis of glycan interaction in gastroenteric viral pathogens. <i>Current Opinion in Virology</i> , 2014, 7, 119-127.	2.6	32
114	Structural Analysis of Determinants of Histo-Blood Group Antigen Binding Specificity in Genogroup I Noroviruses. <i>Journal of Virology</i> , 2014, 88, 6168-6180.	1.5	47
115	A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate's Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2014, 210, 1763-1771.	1.9	122
116	Plasmid-based human norovirus reverse genetics system produces reporter-tagged progeny virus containing infectious genomic RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4043-52.	3.3	60
117	Identification of human single-chain antibodies with broad reactivity for noroviruses. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 339-349.	1.0	28
118	Immunological Detection and Characterization. , 2014, , 47-62.		7
119	Helium beam shadowing for high spatial resolution patterning of antibodies on microstructured diagnostic surfaces. <i>Biointerphases</i> , 2013, 8, 9.	0.6	2
120	Effects of infection and disease with Mycobacterium tuberculosis serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. <i>BMC Infectious Diseases</i> , 2013, 13, 276.	1.3	5
121	Norovirus contamination on French marketed oysters. <i>International Journal of Food Microbiology</i> , 2013, 166, 244-248.	2.1	55
122	Identification and Characterization of a Peptide Affinity Reagent for Detection of Noroviruses in Clinical Samples. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1803-1808.	1.8	20
123	Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 57-60.	0.6	145
124	Prenatal passive transfer of maternal immunity in Asian elephants ( <i>Elephas maximus</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2013, 153, 308-311.	0.5	20
125	Lack of Norovirus Replication and Histo-Blood Group Antigen Expression in 3-Dimensional Intestinal Epithelial Cells. <i>Emerging Infectious Diseases</i> , 2013, 19, 431-438.	2.0	69
126	Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase. <i>Journal of Infectious Diseases</i> , 2013, 207, 974-981.	1.9	203



#	ARTICLE	IF	CITATIONS
127	Environmental Detection of Genogroup I, II, and IV Noroviruses by Using a Generic Real-Time Reverse Transcription-PCR Assay. <i>Applied and Environmental Microbiology</i> , 2013, 79, 6585-6592.	1.4	38
128	Prevalence and control of Norovirus and hepatitis A virus in shellfish. <i>Food Safety Assurance and Veterinary Public Health</i> , 2013, , 137-168.	0.4	3
129	Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes. <i>Journal of Infectious Diseases</i> , 2012, 206, 1069-1077.	1.9	20
130	Picornavirus, the Most Common Respiratory Virus Causing Infection among Patients of All Ages Hospitalized with Acute Respiratory Illness. <i>Journal of Clinical Microbiology</i> , 2012, 50, 506-508.	1.8	20
131	Stem Cell-Derived Human Intestinal Organoids as an Infection Model for Rotaviruses. <i>MBio</i> , 2012, 3, e00159-12.	1.8	216
132	Antibody Responses to Norovirus Genogroup GI.1 and GI.4 Proteases in Volunteers Administered Norwalk Virus. <i>Vaccine Journal</i> , 2012, 19, 1980-1983.	3.2	22
133	Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults. <i>Clinical Infectious Diseases</i> , 2012, 54, 311-317.	2.9	23
134	Serum Hemagglutination Inhibition Activity Correlates with Protection from Gastroenteritis in Persons Infected with Norwalk Virus. <i>Vaccine Journal</i> , 2012, 19, 284-287.	3.2	56
135	Transmission of viruses through shellfish: when specific ligands come into play. <i>Current Opinion in Virology</i> , 2012, 2, 103-110.	2.6	151
136	Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. <i>Vaccine</i> , 2012, 31, 190-195.	1.7	69
137	Norovirus vaccine development: next steps. <i>Expert Review of Vaccines</i> , 2012, 11, 1023-1025.	2.0	48
138	Secretory pathway antagonism by calicivirus homologues of Norwalk virus nonstructural protein p22 is restricted to noroviruses. <i>Virology Journal</i> , 2012, 9, 181.	1.4	20
139	Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans. <i>PLoS ONE</i> , 2012, 7, e50830.	1.1	44
140	Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. <i>PLoS ONE</i> , 2012, 7, e35421.	1.1	485
141	Norovirus Vaccine against Experimental Human Norwalk Virus Illness. <i>New England Journal of Medicine</i> , 2011, 365, 2178-2187.	13.9	429
142	Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. <i>Vaccine</i> , 2011, 29, 8066-8072.	1.7	11
143	Serological Responses to Experimental Norwalk Virus Infection Measured Using a Quantitative Duplex Time-Resolved Fluorescence Immunoassay. <i>Vaccine Journal</i> , 2011, 18, 1187-1190.	3.2	26
144	Structural Analysis of Histo-Blood Group Antigen Binding Specificity in a Norovirus GI.4 Epidemic Variant: Implications for Epochal Evolution. <i>Journal of Virology</i> , 2011, 85, 8635-8645.	1.5	138

#	ARTICLE	IF	CITATIONS
145	Strain-Dependent Norovirus Bioaccumulation in Oysters. <i>Applied and Environmental Microbiology</i> , 2011, 77, 3189-3196.	1.4	115
146	Calicivirus Infections. , 2011, , 411-415.		0
147	Noroviruses: State of the Art. <i>Food and Environmental Virology</i> , 2010, 2, 117-126.	1.5	108
148	Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. <i>Virology</i> , 2010, 406, 1-11.	1.1	88
149	Proteomic Analysis Of Bronchoalveolar Lavage Of Patients With COPD And COPD Exacerbations. , 2010, , .		0
150	Distribution in Tissue and Seasonal Variation of Norovirus Genogroup I and II Ligands in Oysters. <i>Applied and Environmental Microbiology</i> , 2010, 76, 5621-5630.	1.4	128
151	Noroviruses as a Cause of Diarrhea in Travelers to Guatemala, India, and Mexico. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1673-1676.	1.8	47
152	Serological Correlate of Protection against Norovirus-Induced Gastroenteritis. <i>Journal of Infectious Diseases</i> , 2010, 202, 1212-1218.	1.9	233
153	Comprehensive Analysis of a Norovirus-Associated Gastroenteritis Outbreak, from the Environment to the Consumer. <i>Journal of Clinical Microbiology</i> , 2010, 48, 915-920.	1.8	75
154	Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1369-1378.e2.	1.5	71
155	A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. <i>Vaccine</i> , 2010, 28, 3025-3029.	1.7	23
156	A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. <i>Vaccine</i> , 2010, 28, 2076-2079.	1.7	99
157	Intanza <sup>®</sup> : a new intradermal vaccine for seasonal influenza. <i>Expert Review of Vaccines</i> , 2010, 9, 1399-1409.	2.0	53
158	Detection of Human Caliciviruses in Fecal Samples by RT-PCR. <i>Methods in Molecular Biology</i> , 2010, 665, 39-50.	0.4	10
159	Respiratory Virus Infections. <i>Infectious Disease and Therapy</i> , 2010, , 246-271.	0.0	0
160	Gastrointestinal Tract Infections. <i>Infectious Disease and Therapy</i> , 2010, , 272-284.	0.0	0
161	Noroviruses: The leading cause of gastroenteritis worldwide. <i>Discovery Medicine</i> , 2010, 10, 61-70.	0.5	141
162	Detection and Quantification of Noroviruses in Shellfish. <i>Applied and Environmental Microbiology</i> , 2009, 75, 618-624.	1.4	183

#	ARTICLE	IF	CITATIONS
163	A Nosocomial Outbreak of Norovirus Infection Masquerading as <i>Clostridium difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, e75-e77.	2.9	25
164	Vaccines for Pandemic Influenza: Summary of Recent Clinical Trials. <i>Current Topics in Microbiology and Immunology</i> , 2009, 333, 431-451.	0.7	32
165	Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. <i>Vaccine</i> , 2009, 27, 5091-5095.	1.7	52
166	Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. <i>Vaccine</i> , 2009, 27, 5344-5348.	1.7	39
167	Adjuvants for Pandemic Influenza Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2009, 333, 323-344.	0.7	62
168	RHINOVIRUSES. , 2009, , 2170-2193.		0
169	Outcomes of treatment for hematogenous <i>Staphylococcus aureus</i> vertebral osteomyelitis in the MRSA ERA. <i>Journal of Infection</i> , 2008, 57, 128-131.	1.7	74
170	Increased fluoroquinolone resistance with time in <i>Escherichia coli</i> from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. <i>BMC Infectious Diseases</i> , 2008, 8, 4.	1.3	58
171	Sequential Outbreaks of Infections by Distinct <i>Acinetobacter baumannii</i> Strains in a Public Teaching Hospital in Houston, Texas. <i>Journal of Clinical Microbiology</i> , 2008, 46, 198-205.	1.8	31
172	Increasing Doses of an Inactivated Influenza A/H1N1 Vaccine Induce Increasing Levels of Cross-Reacting Antibody to Subsequent, Antigenically Different, Variants. <i>Journal of Infectious Diseases</i> , 2008, 198, 1016-1018.	1.9	13
173	Norwalk Virus Shedding after Experimental Human Infection. <i>Emerging Infectious Diseases</i> , 2008, 14, 1553-1557.	2.0	608
174	Aichi Virus, Norovirus, Astrovirus, Enterovirus, and Rotavirus Involved in Clinical Cases from a French Oyster-Related Gastroenteritis Outbreak. <i>Journal of Clinical Microbiology</i> , 2008, 46, 4011-4017.	1.8	267
175	Chapter 10 Viruses in Shellfish. <i>Perspectives in Medical Virology</i> , 2007, 17, 205-226.	0.1	15
176	Widespread Outbreak of Norovirus Gastroenteritis among Evacuees of Hurricane Katrina Residing in a Large "Megashelter" in Houston, Texas: Lessons Learned for Prevention. <i>Clinical Infectious Diseases</i> , 2007, 44, 1032-1039.	2.9	97
177	Reducing the Dose of Smallpox Vaccine Reduces Vaccine-Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses. <i>Journal of Infectious Diseases</i> , 2007, 195, 826-832.	1.9	17
178	Norwalk Virus RNA Is Infectious in Mammalian Cells. <i>Journal of Virology</i> , 2007, 81, 12238-12248.	1.5	141
179	Immunopathogenesis of Respiratory Syncytial Virus Bronchiolitis. <i>Journal of Infectious Diseases</i> , 2007, 195, 1532-1540.	1.9	115
180	A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. <i>Vaccine</i> , 2007, 25, 5367-5373.	1.7	51

#	ARTICLE	IF	CITATIONS
181	Preparing for a possible pandemic: influenza A/H5N1 vaccine development. <i>Current Opinion in Pharmacology</i> , 2007, 7, 484-490.	1.7	19
182	Portable 24-analyte surface plasmon resonance instruments for rapid, versatile biodetection. <i>Biosensors and Bioelectronics</i> , 2007, 22, 2268-2275.	5.3	135
183	Oral step-down therapy is comparable to intravenous therapy for <i>Staphylococcus aureus</i> osteomyelitis. <i>Journal of Infection</i> , 2007, 54, 539-544.	1.7	83
184	The Epidemiologic and Clinical Importance of Norovirus Infection. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 275-290.	1.0	264
185	Influenza vaccine in patients with asthma. <i>Expert Review of Vaccines</i> , 2006, 5, 111-118.	2.0	4
186	Norwalk Virus-specific Binding to Oyster Digestive Tissues. <i>Emerging Infectious Diseases</i> , 2006, 12, 931-936.	2.0	218
187	Noroviruses everywhere: has something changed?. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 467-474.	1.3	182
188	Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations. <i>Clinical Infectious Diseases</i> , 2006, 43, 1135-1142.	2.9	140
189	Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons. <i>Archives of Internal Medicine</i> , 2006, 166, 1121.	4.3	156
190	Recovery of Drug-Resistant Influenza Virus from Immunocompromised Patients: A Case Series. <i>Journal of Infectious Diseases</i> , 2006, 193, 760-764.	1.9	253
191	Molecular Methods of Virus Detection in Foods. , 2006, , 121-149.		4
192	Bacteraemia in the elderly: predictors of outcome in an urban teaching hospital. <i>Journal of Infection</i> , 2005, 50, 288-295.	1.7	38
193	Respiratory viral infections in patients with chronic, obstructive pulmonary disease. <i>Journal of Infection</i> , 2005, 50, 322-330.	1.7	154
194	Norwalk virus infection associates with secretor status genotyped from sera. <i>Journal of Medical Virology</i> , 2005, 77, 116-120.	2.5	148
195	Editorial Commentary: Uncommon(ly Considered) Manifestations of Infection with Rhinovirus, Agent of the Common Cold. <i>Clinical Infectious Diseases</i> , 2005, 41, 266-267.	2.9	22
196	Replication and packaging of Norwalk virus RNA in cultured mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10327-10332.	3.3	99
197	The Role of Immune Reconstitution Inflammatory Syndrome in AIDS-Related <i>Cryptococcus neoformans</i> Disease in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 40, 1049-1052.	2.9	309
198	Use of Rotavirus Virus-Like Particles as Surrogates To Evaluate Virus Persistence in Shellfish. <i>Applied and Environmental Microbiology</i> , 2005, 71, 6049-6053.	1.4	61

#	ARTICLE	IF	CITATIONS
199	Immune Response to Influenza Vaccine in Adult HCV Patients Receiving Peginterferon and Ribavirin Therapy. <i>American Journal of Gastroenterology</i> , 2005, 100, S128.	0.2	0
200	Laboratory efforts to cultivate noroviruses. <i>Journal of General Virology</i> , 2004, 85, 79-87.	1.3	517
201	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 717-724.	1.5	93
202	Norovirus disease: changing epidemiology and host susceptibility factors. <i>Trends in Microbiology</i> , 2004, 12, 279-287.	3.5	284
203	Rotavirus VLP2/6: a new tool for tracking rotavirus in the marine environment. <i>Research in Microbiology</i> , 2004, 155, 575-578.	1.0	12
204	Inactivated influenza vaccination for people with spinal cord injury. <i>Archives of Physical Medicine and Rehabilitation</i> , 2004, 85, 1886-1889.	0.5	17
205	A semiquantitative approach to estimate Norwalk-like virus contamination of oysters implicated in an outbreak. <i>International Journal of Food Microbiology</i> , 2003, 87, 107-112.	2.1	101
206	Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable <i>Haemophilus influenzae</i> . <i>FEMS Immunology and Medical Microbiology</i> , 2003, 37, 69-75.	2.7	60
207	Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. <i>Vaccine</i> , 2003, 21, 3479-3482.	1.7	186
208	Norwalk Virus-Like Particle Hemagglutination by Binding to H Histo-Blood Group Antigens. <i>Journal of Virology</i> , 2003, 77, 405-415.	1.5	230
209	Biopsy Neutrophilia, Neutrophil Chemokine and Receptor Gene Expression in Severe Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 968-975.	2.5	312
210	Practical and Sensitive Screening Strategy for Detection of Influenza Virus. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4353-4356.	1.8	19
211	Infections in Hispanic Immigrants. <i>Clinical Infectious Diseases</i> , 2002, 34, 1627-1632.	2.9	40
212	Clinical Responses to Undiluted and Diluted Smallpox Vaccine. <i>New England Journal of Medicine</i> , 2002, 346, 1265-1274.	13.9	263
213	Norwalk Virus Infection and Disease Is Associated with ABO Histo-Blood Group Type. <i>Journal of Infectious Diseases</i> , 2002, 185, 1335-1337.	1.9	429
214	Immune Reconstitution Inflammatory Syndrome. <i>Medicine (United States)</i> , 2002, 81, 213-227.	0.4	496
215	Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. <i>Vaccine</i> , 2001, 19, 4635-4643.	1.7	35
216	Development of a Reverse Transcription-PCR-DNA Enzyme Immunoassay for Detection of Norwalk-Like Viruses and Hepatitis A Virus in Stool and Shellfish. <i>Applied and Environmental Microbiology</i> , 2001, 67, 742-749.	1.4	72

#	ARTICLE	IF	CITATIONS
217	Diagnosis of Noncultivable Gastroenteritis Viruses, the Human Caliciviruses. <i>Clinical Microbiology Reviews</i> , 2001, 14, 15-37.	5.7	333
218	Development of an immunomagnetic capture reverse transcription-PCR assay for the detection of Norwalk virus. <i>Journal of Virological Methods</i> , 2000, 90, 69-78.	1.0	59
219	Development of Methods To Detect "Norwalk-Like Viruses" (NLVs) and Hepatitis A Virus in Delicatessen Foods: Application to a Food-Borne NLV Outbreak. <i>Applied and Environmental Microbiology</i> , 2000, 66, 213-218.	1.4	148
220	Comparison of a New Neuraminidase Detection Assay with an Enzyme Immunoassay, Immunofluorescence, and Culture for Rapid Detection of Influenza A and B Viruses in Nasal Wash Specimens. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1161-1165.	1.8	82
221	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. <i>New England Journal of Medicine</i> , 1999, 341, 1336-1343.	13.9	477
222	Chlamydia species and Mycoplasma pneumoniae. <i>Current Infectious Disease Reports</i> , 1999, 1, 73-79.	1.3	3
223	Influenza A virus outbreak in a neonatal intensive care unit. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 811-815.	1.1	122
224	Common Emergence of Amantadine- and Rimantadine-Resistant Influenza A Viruses in Symptomatic Immunocompromised Adults. <i>Clinical Infectious Diseases</i> , 1998, 26, 1418-1424.	2.9	160
225	Acute Respiratory Failure Associated with Cryptococcosis in Patients with AIDS: Analysis of Predictive Factors. <i>Clinical Infectious Diseases</i> , 1998, 27, 1231-1237.	2.9	70
226	Respiratory Tract Viral Infections in Inner-City Asthmatic Adults. <i>Archives of Internal Medicine</i> , 1998, 158, 2453.	4.3	194
227	Distribution of Norwalk Virus within Shellfish Following Bioaccumulation and Subsequent Depuration by Detection Using RT-PCR. <i>Journal of Food Protection</i> , 1998, 61, 1674-1680.	0.8	170
228	Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice. <i>Journal of Virology</i> , 1998, 72, 1345-1353.	1.5	147
229	Dual Respiratory Virus Infections. <i>Clinical Infectious Diseases</i> , 1997, 25, 1421-1429.	2.9	134
230	Effects of Requiring prior Authorization for Selected Antimicrobials: Expenditures, Susceptibilities, and Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 1997, 25, 230-239.	2.9	351
231	Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-12. This paper was presented at the First International Conference on Immunology and Aging, June 13-19, 1996, Bethesda, MD, USA. <i>Mechanisms of Ageing and Development</i> , 1997, 94, 25-39.	2.2	61
232	Nonculturable agents of viral gastroenteritis. <i>Clinical Microbiology Newsletter</i> , 1997, 19, 177-182.	0.4	2
233	Typing and subtyping clinical isolates of influenza virus using reverse transcription-polymerase chain reaction. <i>Clinical and Diagnostic Virology</i> , 1996, 7, 77-84.	1.8	26
234	Enforcing antimicrobial restrictions. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 796-797.	0.5	1

#	ARTICLE	IF	CITATIONS
235	Unanticipated Diagnoses Found at Autopsy in an Urban Public Teaching Hospital. American Journal of the Medical Sciences, 1996, 311, 215-220.	0.4	33
236	Infections Associated with the Consumption of Goat Cheese. Journal of Travel Medicine, 1995, 2, 178-181.	1.4	2
237	Comparison of Trivalent Cold-Adapted Recombinant (CR) Influenza Virus Vaccine with Monovalent CR Vaccines in Healthy Unselected Adults. Journal of Infectious Diseases, 1995, 172, 253-257.	1.9	18
238	Life-Threatening Pseudomonas aeruginosa Infections in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1992, 14, 403-411.	2.9	130
239	Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine, 1990, 8, 217-224.	1.7	29
240	Binding and Inactivation of Viruses on and in Food, with a Focus on the Role of the Matrix. , 0, , 189-208.		10
241	Viral Pathogens of the Intestine. , 0, , 525-545.		3
242	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infectious Diseases, 0, , .	0.4	1